MedPath

Comparison of Three Transfusion Strategies for Central Venous Catheterization in Cirrhotics: A Randomized Clinical Trial

Not Applicable
Terminated
Conditions
Liver Cirrhosis
Interventions
Other: Thromboelastometry-based protocol
Other: Coagulogram-based protocol
Other: Restrictive strategy
Registration Number
NCT02311985
Lead Sponsor
Hospital Israelita Albert Einstein
Brief Summary

The aim of this study is to compare three different blood transfusion strategies for coagulopathy correction before central venous catheterization in patients with chronic liver failure (cirrhosis and/or chronic liver graft dysfunction) admitted in intensive care unit.

Detailed Description

Central venous catheterization is a ubiquitous procedure in intensive care units and is mainly used for drug administration, hemodynamic monitoring and hemodialysis. Only in US more than five million catheters are inserted annually. One of the main complications associated to central venous lines are the mechanical ones, i.e. arterial puncture, bleeding and hematoma formation, which varies between 5% and 19%. The use of real-time ultrasonography to accomplish central venous catheterization was associated to a drastic reduction in complication rates, and when performed by trained personnel, some series show complications rates \<1%, even in patients with coagulopathy.

Patients presenting with chronic liver failure has a complex coagulation system balance, resulting from reduction in the majority of procoagulant and anticoagulant factors, opposed by preservation of thrombin generation. Thus, these patients are prone to develop hemorrhagic and thrombotic phenomena. The coagulation of cirrhotic patients have been classically evaluated by standard coagulation tests. Nevertheless, these tests present important limitations, as evaluation of plasmatic component only, and do not predict bleeding risk. The thromboelastometry is a point-of-care real-time coagulation system evaluation with the advantage of evaluating the cellular and plasmatic components of the coagulation and present a more comprehensive evaluation of blood coagulation, specially in cirrhotics. This technology is associated with reduced costs in diverse clinical settings.

In clinical practice, approximately 90% of physicians empirically transfuse blood components to cirrhotic patients before invasive procedures. This practice is associated to increased risks related to blood transfusion per se, e.g. blood borne infections, immunologic and non-immunologic adverse reactions, to cite some. Several randomized clinical trials have shown that restrictive blood transfusion strategies are associated to better outcomes, including mortality.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
57
Inclusion Criteria
  • Chronic liver failure (cirrhosis or chronic graft dysfunction) from any cause and medical indication of central venous line placement
Exclusion Criteria
  • Acute liver failure or
  • Use of therapeutic doses of oral or parenteral anticoagulants (unfractionated heparin or low molecular weight heparin or oral anticoagulants) or
  • Use of oral or parenteral platelet aggregation inhibitors or
  • Patients with von Willebrand syndrome or
  • Over-the-guidewire central venous catheter changing
  • Patients previously included in this study protocol during the same hospital stay

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Thromboelastometry-based protocolThromboelastometry-based protocolArm based on rotational thromboelastometry (ROTEM(R)) protocol to guide blood transfusion before central venous catheterization. The possible components to be used include fresh frozen plasma, platelets (random or aphaeresis) and or cryoprecipitate.
Coagulogram-based protocolCoagulogram-based protocolArm based on standard coagulation tests protocol to guide blood transfusion before central venous catheterization. The possible components to be used include fresh frozen plasma, platelets (random or aphaeresis) and or cryoprecipitate.
Restrictive strategyRestrictive strategyArm based on a restrictive protocol strategy based on INR/PT and platelets count. The possible components to be used include fresh frozen plasma and/or platelets (random or aphaeresis).
Primary Outcome Measures
NameTimeMethod
Proportion of patients submitted to blood components transfusion - i.e. fresh frozen plasma, platelets and/or cryoprecipitate - before central venous catheterizationDay of randomization
Secondary Outcome Measures
NameTimeMethod
Length of stay in ICUUp to 90 days
Incidence of hemorrhagic complications associated to central venous catheterization procedureDay 1
Incidence of acute immunologic and non-immunologic adverse effects of blood transfusionDay 1
Costs assessments (laboratory and blood transfusion) between the three strategiesDay 1
Length of stay in hospitalUp to 180 days
Mortality rateUp to 28 days

Trial Locations

Locations (1)

Hospital Israelita Albert Einstein

🇧🇷

Sao Paulo, SP, Brazil

© Copyright 2025. All Rights Reserved by MedPath